• E-mail :[email]
  • Phone : +33 4 89 06 42 34
  • Location : Nice, France
Last update 2018-07-09 08:21:01.992

Philippe Gual Ph.D., Team Leader, Research Director (DR2 INSERM),

Course and current status

University Degrees:

-2007: Authorization to supervise research (HDR), University of Nice Sophia Antipolis, Nice France

-1997: Ph.D. in Endocrinology, University of Marseille, France.

Scientific Career

-Since 2018: Team Leader, Team 8 “Chronic liver diseases associated with obesity and alcohol”, INSERM  U1065, Nice

-2008-2017: Co-Team Leader, Team 8 “Hepatic complications of obesity”, INSERM U1065, Nice

-2011: Research director (DR2 INSERM)

-2007-2011: Contract of interface between INSERM and the Hospital.

-2003-2007: Researcher (CR1 INSERM), INSERM U568, Nice (Y. Le Marchand-Brustel),

-2000-2003: Post-doctoral Training course, INSERM U568, Nice, (Y. Le Marchand-Brustel)

-1997-2000: Post-doctoral training course, Institute of Research against Cancer and Treatment, Turin, Italy, (Pr. PM Comoglio)

Teaching and Training

Training of 15 Master students, 6 PhD students, 1 Post doc

Lectures for scientific societies (Obesity, Hepatology)

Course on "liver complications of obesity" for the Masters of “Nutrition and vascular pathology"” (University of Aix-Marseille) and of "Pharmacology, physiopathology and neurobiology" (University of Nice)

Scientific Activity and Expertise

Thesis or HDR defence committee: 25

Peer reviewer of grant proposals: CODDIM/CORDDIM, 29/05/2009 au 23/08/2014 (n=29); AFEF, depuis 2016 (n=99); ANR, 2018 (n=1), Cancéropole Grand Ouest, 2018 (n=1).

Peer reviewer of scientific articles: Journal of Hepatology, Hepatology, Diabetes,……..

Member of evaluation Committee of Research laboratory: HCERES, Centre de Recherche des Cordeliers, 2018

Editorial Board: Frontiers in Physiology since 2011; Journal of Obesity since 2016

Member of Study group: since 2011: EASD NAFLD Study group; 2006-2011« Groupe d’Étude et de Recherche   sur le Syndrome métabolique et la stéato-hépatite » (GERS) (Roche)

Member of organizing meetings: 6 national meetings: "3èmes Journées Scientifiques du Club Francophone de    l'AuTophaGie" Grasse 2013; "81èmes Journées Scientifiques de l'AFEF" Lyon, 2017; "Journées Francophones hépato-gastroentérologie et d'oncologie digestive" Paris, 2017 ; "83èmes Journées Scientifiques de l'AFEF" Lyon, 2018; "Journées Francophones hépato-gastroentérologie et d'oncologie digestive" Paris, 2018; " Journées Francophones de Nutrition JFN 2018 " Nice, 2018

Moderator of meeting session: Société Francophone du Diabète, Journées Francophones de     Nutrition, Association Française d'Étude et de Recherche sur l'Obesité, EFSD/Lilly Symposium, Association Française pour l'Étude du Foie

Board member of the "Association Française pour l'Étude du Foie"

National and international meetings: 126 selected Abstract

National and international invited lecture: 17

Publications in peer-review journals: 88 (65 articles, 23 reviews/letters/editorials/book chapter)

Scientific summary

The aims of the Inserm team directed by Philippe Gual and composed of clinicians and basic scientists, is to better understand the hepatic complications associated with obesity (Non alcoholic fatty liver disease: NAFLD) and, more recently, with chronic alcohol consumption (alcoholic liver disease, ALD). These chronic liver diseases range from steatosis to steatohepatitis (Non Alcoholic or Alcoholic Steatohepatitis, NASH and ASH), fibrosis, cirrhosis and finally hepatocellular carcinoma. NAFLD and ALD are the main causes of cirrhosis and increase the risk of liver-related death and hepatocellular carcinoma. NASH and ALD are also the most common indications for liver transplantation in the United States. Our translational research mainly focus on

1) The identification of new markers/actors of the progression of NAFLD and ALD. We take advantage of our cohorts of obese (n=1006) and alcoholic patients (n=173) and "omics" approaches. For the previous years, our research contributed to the identification of a genetic signature of “NASH”, the design of a non-invasive composite model capable of predicting accurately NASH; the highlighting that consumption of regular coffee is an independent protective factor for liver fibrosis and vitamin D deficiency could have an impact in the severity of liver complications;

2) The study of potential players in the progression of NAFLD including the Osteopontin/CD44, endoplasmic reticulum stress and ILCs pathways. The impact of targeting these pathways is investigated in mice. We have already reported that Osteopontin/CD44 pathway is involved in the progression of liver complications in mice and humans by acting in both liver and adipose tissue inflammation; enrichment of specific dendritic cells in adipose tissue regulates adipose tissue immune responses in mice and humans and the targetting of the endoplasmic reticulum stress (IRE1a) corrected the steatohepatitis in mouse.

3) The study of the interaction between alcohol and obesity in the severity of fatty liver disease in mouse and human.

The results of the present project should bring new insights in the overall understanding of the mechanistic of hepatic complications induced by obesity and chronic alcohol consumption and to propose better diagnostic and therapeutic approaches.

Image d’exemple